Literature DB >> 29496822

Polyethylene Glycol Fusion for Hybridoma Production.

Edward A Greenfield.   

Abstract

Once a good immune response has developed in an animal and an appropriate screening procedure has been developed, the construction of hybridomas is ready to begin. Polyethylene glycol (PEG) is the fusing agent of choice for hybridoma production, allowing the rapid and manageable fusion of mammalian cells. PEG fuses the plasma membranes of adjacent myeloma and/or antibody-secreting cells, forming a single cell with two or more nuclei. This heterokaryon retains these nuclei until the nuclear membranes dissolve before mitosis. In this protocol, antibody-secreting cells are isolated from the appropriate lymphoid tissue (mouse spleen and lymph nodes), mixed with myeloma cells, centrifuged to generate good cell-to-cell contacts, and fused with PEG. The fused cells are then diluted into selective medium and plated in multiwell tissue culture dishes. Beginning ∼1 wk later, samples of the tissue culture supernatants are removed from wells that contain growing hybridomas and tested for the presence of the appropriate antibodies. Cells from positive wells are grown, single-cell-cloned, and frozen. A procedure for screening batches of PEG for efficacy before hybridoma fusion is also included.
© 2018 Cold Spring Harbor Laboratory Press.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 29496822     DOI: 10.1101/pdb.prot103176

Source DB:  PubMed          Journal:  Cold Spring Harb Protoc        ISSN: 1559-6095


  5 in total

Review 1.  To PEGylate or not to PEGylate: Immunological properties of nanomedicine's most popular component, polyethylene glycol and its alternatives.

Authors:  Da Shi; Damian Beasock; Adam Fessler; Janos Szebeni; Julia Y Ljubimova; Kirill A Afonin; Marina A Dobrovolskaia
Journal:  Adv Drug Deliv Rev       Date:  2021-12-10       Impact factor: 15.470

2.  The mucin-like, secretory type-I transmembrane glycoprotein GP900 in the apicomplexan Cryptosporidium parvum is cleaved in the secretory pathway and likely plays a lubrication role.

Authors:  Xiaohui Li; Jigang Yin; Dongqiang Wang; Xin Gao; Ying Zhang; Mingbo Wu; Guan Zhu
Journal:  Parasit Vectors       Date:  2022-05-17       Impact factor: 4.047

3.  Novel PD-L1 mAb HC16 reveals upregulation of PD-L1 in BAC subtype.

Authors:  Bor-Chyuan Su; Chen-Hung Ting; Kang-Yun Lee; Sheng-Ming Wu; Po-Hao Feng; Yao-Fei Chan; Jyh-Yih Chen
Journal:  Histol Histopathol       Date:  2020-10-28       Impact factor: 2.303

Review 4.  Virus-Induced Membrane Fusion in Neurodegenerative Disorders.

Authors:  Carolina Osorio; Adonis Sfera; Jonathan J Anton; Karina G Thomas; Christina V Andronescu; Erica Li; Rayan W Yahia; Andrea García Avalos; Zisis Kozlakidis
Journal:  Front Cell Infect Microbiol       Date:  2022-03-24       Impact factor: 6.073

5.  A Novel Tau Antibody Detecting the First Amino-Terminal Insert Reveals Conformational Differences Among Tau Isoforms.

Authors:  Joke Verelst; Nick Geukens; Sabiha Eddarkaoui; Dorien Vliegen; Elien De Smidt; Joëlle Rosseels; Vanessa Franssens; Sofie Molenberghs; Cindy Francois; Erik Stoops; Maria Bjerke; Sebastiaan Engelborghs; Mohamed Laghmouchi; Sofie Carmans; Luc Buée; Eugeen Vanmechelen; Joris Winderickx; Debby Thomas
Journal:  Front Mol Biosci       Date:  2020-03-31
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.